Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Clevegen (bexmarilimab)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Faron Pharma

Drug class:

STAB1 inhibitor

‹

›

IFNG-L	Cholangiocarcinoma	IFNG-L	Cholangiocarcinoma	bexmarilimab Sensitive: C3 – Early Trials bexmarilimab Sensitive : C3	bexmarilimab Sensitive: C3 – Early Trials bexmarilimab Sensitive : C3
TNFA-L	Cholangiocarcinoma	TNFA-L	Cholangiocarcinoma	bexmarilimab Sensitive: C3 – Early Trials bexmarilimab Sensitive : C3	bexmarilimab Sensitive: C3 – Early Trials bexmarilimab Sensitive : C3
IFNG-L	Melanoma	IFNG-L	Melanoma	bexmarilimab Sensitive: C3 – Early Trials bexmarilimab Sensitive : C3	bexmarilimab Sensitive: C3 – Early Trials bexmarilimab Sensitive : C3
TNFA-L	Melanoma	TNFA-L	Melanoma	bexmarilimab Sensitive: C3 – Early Trials bexmarilimab Sensitive : C3	bexmarilimab Sensitive: C3 – Early Trials bexmarilimab Sensitive : C3
IFNG-L	Gastric Cancer	IFNG-L	Gastric Cancer	bexmarilimab Sensitive: C3 – Early Trials bexmarilimab Sensitive : C3	bexmarilimab Sensitive: C3 – Early Trials bexmarilimab Sensitive : C3
TNFA-L	Gastric Cancer	TNFA-L	Gastric Cancer	bexmarilimab Sensitive: C3 – Early Trials bexmarilimab Sensitive : C3	bexmarilimab Sensitive: C3 – Early Trials bexmarilimab Sensitive : C3